Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gene therapy
Pharma
2nd patient dies after Sarepta's DMD gene therapy Elevidys
Sarepta has suspended giving Elevidys to non-ambulatory DMD patients in the commercial setting while it seeks FDA approval of a risk mitigation plan.
Angus Liu
Jun 16, 2025 10:58am
bluebird investors get on board with sale to Carlyle, SK Capital
May 30, 2025 11:50am
Biopharma briefing: Q1 trends, gene therapy news, ASCO preview
May 30, 2025 9:46am
Novartis, Sarepta tipped to drive genomic therapy sales boom
May 15, 2025 12:18pm
Bluebird investor reluctance pays off with better buyout offer
May 14, 2025 10:40am
Bluebird warns of potential bankruptcy amid buyout delay
May 13, 2025 9:56am